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Abstract 
The aim of this study was to investigate remission and biologic-free remission after orthopaedic surgery and related 
clinical factors in non-responder to infliximab for rheumatoid arthritis (RA). We analyzed 74 patients who were treated 
with 3 mg/kg infliximab and methotrexate and underwent orthopaedic surgery after non-responder to infliximab 
with disease activity score (DAS) 28 (CRP) of ≥3.2. The rates of remission and biologic-free remission at 52 weeks 
after orthopaedic surgery were investigated and the clinical factors related to remission and biologic-free remis-
sion were analyzed by logistic regression and receiver-operating characteristic analyses. The rates of total remission 
and biologic-free remission were 37/74 (50 %) and 9/74 (12.2 %), respectively. Regarding orthopaedic surgery, the 
rates of remission and biologic-free remission were 25/38 (65.8 %) and 7/38 (18.4 %) for synovectomy, 7/20 (35 %) 
and 0/20 (0 %) for arthroplasty, and 5/16 (31.3 %) and 2/16 12.5) for others including spine surgery and foot surgery. 
DAS28(CRP) at baseline was significantly related to both remission and biologic-free remission. Prednisolone was 
negatively associated with remission, and DAS28(CRP) was related to biologic-free remission by logistic regression 
analyses. DAS28(CRP) below 3.7 was cutoff point for acquiring biologic-free remission of non-responder to infliximab 
after orthopaedic surgery. Therefore orthopaedic surgery may be effective to obtain remission or biologic-free remis-
sion in RA patients treated with biologics.
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Background
Anti-tumor necrosis factor (TNF)-α therapy such as inf-
liximab for rheumatoid arthritis (RA) is used not only to 
inhibit inflammation, but also to suppress bone and joint 
destruction. It is reported that infliximab leads biologic-
free remission in the long term for early RA patients with 
good responses (van der Kooij et al. 2009; Bejarano et al. 
2010; Quinn et al. 2005; van der Bijl et al. 2007; van den 
Broek et al. 2011). However, it is difficult to induce bio-
logic-free remission in non-responder to infliximab. No 
reports to date have described how orthopaedic surgery 
contributes to remission or biologic-free remission. Anti-
TNF-α therapy cannot improve the clinical outcomes in 
some patients with joint swelling and tenderness with 
bone destruction and synovium proliferation, and such 
patients are indicated to undergo orthopaedic surgery, 
such as total arthroplasty or arthroscopic synovectomy 
(Momohara et  al. 2011; Kanbe and Inoue 2006). How-
ever, it remains unclear which orthopaedic surgeries are 
suitable for the induction of remission as well as biologic-
free remission in infliximab treatment, and how clinical 
factors are related to these outcomes. In this study, we 
treated 74 patients by orthopaedic surgery among cases 
with non-responder to infliximab [disease activity score 
(DAS) 28 (CRP) of ≥3.2]. Retrospective and case studies 
were analyzed to detect specific factors related to remis-
sion and biologic-free remission after orthopaedic sur-
gery under treatment with infliximab in RA. This is the 
first report related to bio-free remission by orthopaedic 
surgery for RA.
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Methods
Patients and methods
Seventy-four patients (9 males and 65 females) with a 
mean age of 60.4 ± 1.05 years, mean disease duration of 
12.29 ± 11.78 years, mean disease activity score (DAS) 28 
(CRP) of 4.32 ± 0.71, mean CRP of 2.67 ± 3.22 mg/dL, 
mean methotrexate (MTX) dose of 6.02 ± 1.17 mg/week, 
and mean prednisolone (PSL) dose of 3.68 ± 2.29 mg/day 
were treated by orthopaedic surgery in non-responder to 
3 mg/kg infliximab for a mean period of 1.15 ± 0.53 years 
(Table 1). The 74 orthopaedic surgeries included 38 syn-
ovectomy procedures in 33 knees, three shoulders, one 
elbow, and one wrist, 20 arthroplasty procedures com-
prising 8 total knee arthroplasties (TKA), three total 
hip arthroplasties (THA), five total shoulder arthroplas-
ties (TSA), three total elbow arthroplasties (TEA), and 
one total ankle arthroplasty (TAA), and 16 other proce-
dures comprising six spine surgeries, eight foot surger-
ies, and two hand surgeries. The rehabilitation was also 
performed after all orthopaedic procedures. The treat-
ment of infliximab was stopped around 4  weeks before 
surgery and restarted approximately around 4  weeks 
after surgery. MTX was stopped only one week of sur-
gery, however PSL was continued. The infliximab treat-
ment included a diagnosis of RA based on the American 
College of Rheumatology (ACR) criteria (Arnett et  al. 
1988), and categorization according to Steinbrocker et al. 
(Steinbrocker et al. 1949). The disease stages were stage 
II in 16 patients, stage III in 40 patients, and stage IV in 
18 patients. The classes were class 2 in 20 patients, class 
3 in 46 patients, and class 4 in 8 patients. At 52  weeks 
after surgery, the DAS28(CRP) was analyzed for the rates 
of remission, DAS28(CRP) of ≤2.6, and biologic-free 
remission (Hirata et al. 2013; van der Heijde et al. 1990). 
Biologic-free remission was obtained after remission 
accomplished at 24 weeks after surgery. Logistic regres-
sion analyses were performed for age, disease duration, 
DAS28(CRP), dose of PSL, dose of MTX, stages and class 
at baseline. Receiver-operating characteristic (ROC) 
analyses were performed to acquire the cutoff points with 
sensitivity and specificity related to the significant clinical 
factors. Informed consent was obtained from all patients, 
and the study protocol was approved by the ethics com-
mittee of Tokyo Women’s Medical University (approval 
number 1321).
Statistical analysis
The Wilcoxon signed-rank test was used to compare 
the DAS28(CRP) scores at baseline and 52  weeks after 
orthopaedic surgery. Logistic regression analyses related 
to remission and biologic-free remission were, respec-
tively carried out at 52 weeks using StatFlex version 6.0 
(Statflex, Tokyo, Japan). ROC curves were calculated to 
acquire the sensitivity and specificity with odds ratios of 
the clinical factors using the above software. Values of 
p < 0.05 were considered significant.
Results
The remission rate of the total patients at 52 weeks was 
37/74 (50 %), including 25/38 (65.8 %) for synovectomy, 
7/20 (35  %) for arthroplasty, and 5/16 (31.3  %) for oth-
ers (Table  2). The biologic-free remission rate was 9/74 
(12.2  %), including 7/38 (18.4  %) for synovectomy, 
0/20 (0  %) for arthroplasty, and 2/16 (12.5  %) for oth-
ers (Table 2). The Boolean remission was 27/74 (36.5 %) 
and bio-free Boolean remission was 8/74 (10.8  %) after 
surgery. The rates of remission and biologic-free remis-
sion continued, being 19/37 (51.4 %) and 7/9 (77.8 %) at 
104  weeks after orthopaedic surgery, respectively. The 
logistic regression analyses showed that DAS28(CRP) at 
baseline (p = 0.0025) and PSL (p = 0.0348) were related 
to remission (Table  3). Therefore, low DAS28(CRP) at 
baseline and low dose of PSL were significantly correlated 
with remission. However, the logistic regression analyses 
showed that DAS28(CRP) at baseline (p = 0.0401) were 
related to biologic-free remission (Table  4). Therefore, 
low DAS28(CRP) at baseline was significantly correlated 
with biologic-free remission after orthopaedic surgery. 
Table 1 Patients backgrounds at base line for orthopaedic 
surgery
DD disease duration, DAS disease activity score, CRP c-reactive protein, MTX 
methotrexate, PSL predonisolone
N 74
Age (years) 60.4 ± 1.05
Female (%) 65/74 (87.8 %)
DD (years) 12.29 ± 11.78
DAS28(CRP) 4.32 ± 0.71
CRP (mg/dl) 2.67 ± 3.22
MTX (mg/week) 6.02 ± 1.17
PSL (mg/day) 3.68 ± 2.29
Stage/class II; 16, III; 40, IV; 18/2; 20, 3; 46, 4; 8
Infliximab (years) 1.15 ± 0.53
Orthopaedic surgery Synovectomy 38
Arthroplasty 20
Others 16









37/74 (50 %) 25/38 
(65.8 %)
7/20 (35 %) 5/16 (31.3 %)
Bio-free rate 9/74 (12.2 %) 7/38 (18.4 %) 0/20 (0 %) 2/16 (12.5 %)
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The DAS28(CRP) at baseline differed significantly, being 
4.428  ±  0.685 in the no biologic-free remission group 
and 3.567  ±  0.265 in the biologic-free remission group 
(p < 0.0004) (Fig. 1). The ROC analyses showed that the 
cutoff point for DAS28(CRP) was 3.7, with sensitivity of 
0.78, specificity of 0.83, and odds ratio of 17.2  (Fig.  2). 
Therefore, DAS28(CRP) below 3.7 was significantly cor-
related with obtaining biologic-free remission after 
orthopaedic surgery in treatment of non-responder to 
infliximab for RA (Fig. 2).    
Discussion
Biologic-free treatment in RA was first reported in the 
TNF20 study (Bejarano et  al. 2010; Quinn et  al. 2005). 
Patients with early RA who had experienced symptoms 
for <12 months were treated with a combination of inflix-
imab and MTX. Patients who initiated treatment with inf-
liximab and MTX achieved higher American College of 
Rheumatology 50 and 70 % improvement responses than 
patients who initiated therapy with MTX and placebo. At 
1 year after stopping the induction therapy, the response 
was sustained in 70 % of patients who received infliximab 
and MTX. In the Best study, it was described that inflixi-
mab had potential for biologic-free remission in the long-
term results, with 56  % discontinuation of infliximab at 
≥6  months and 52  % at 7.2  years (van der Kooij et  al. 
2009; van der Bijl et al. 2007; van den Broek et al. 2011). 
Other biologics such as adalimumab were also reported 
for biologic-free remission, as 58 % of patients achieved 
adalimumab-free remission at the primary end point of 
6  months after discontinuation of adalimumab (Felson 
et al. 2011). However, there is no evidence for acquisition 
Table 3 Clinical factors related to the remission
DD disease duration, DAS disease activity score, PSL predonisolone, MTX 
methotrexate
Factors P Odds 95 % CI
Age 0.5574 0.97981 0.91525–1.04892
DD 0.7197 0.99877 0.99207–1.00551
DAS28 0.0025 0.03237 0.00351–0.29830
PSL 0.0348 0.53672 0.30112–0.95665
MTX 0.6036 1.26905 0.51632–3.11920
Stage 0.6344 1.56574 0.24664–9.93964
Class 0.1442 0.33875 0.07925–1.44801
Table 4 Clinical factors related to  the biologic-free remis-
sion
DD disease duration, DAS disease activity score, PSL predonisolone, MTX 
methotrexate
Factors P Odds 95 % CI
Age 0.0875 1.27742 0.96462–1.69165
DD 0.3805 0.9947 0.98294–1.00659
DAS28 0.0401 0.00284 0.00001–0.76627
PSL 0.3289 1.53217 0.65064–3.60805
MTX 0.9742 0.98265 0.34078–2.83353
Stage 0.8398 0.64611 0.00936–44.5802
Class 0.9247 1.18464 0.03524–39.8251
Fig. 1 DAS28(CRP) values after orthopaedic surgery in non-
responder to the cases of infliximab at 52 weeks regarding biologic-
free remission
Fig. 2 ROC curves of biologic-free remission after orthopaedic sur-
gery to analyze the cutoff points, sensitivities, specificities, and odds 
ratios regarding to DAS28(CRP)
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of remission or biologic-free remission of non-responder 
to infliximab in RA. We previously reported that syn-
ovectomy was effective for non-responder cases of inf-
liximab to improve the DAS28 after surgery (Kanbe and 
Inoue 2006). Arthroplasty was also reported as a method 
for restoring biologic efficacy (Momohara et  al. 2011). 
Although the mechanism for non-responder to inflixi-
mab is unknown, serum levels of IL-6 were upregulated, 
even with the use of TNF-α blockers (Takeuchi et  al. 
2012). It was reported that TNF-α expression in the syn-
ovium was correlated with DAS28(CRP) by immunohis-
tochemistry (Kanbe et  al. 2013). Orthopaedic surgery 
may have a role in removing the synovium containing 
TNF-α and other cytokines, thereby reducing the inflam-
mation to maintain biologic efficacy. This study showed 
50  % remission after orthopaedic surgery even under 
non-responder of infliximab and 12.2  % biologic-free 
remission. In particular, synovectomy was more effec-
tive than other surgical treatments, meaning that direct 
removal of synovial tissue might be useful for inflixi-
mab toleration. The baseline DAS28(CRP) played a role 
in predicting the efficacy of orthopaedic surgery for 
remission as well as biologic-free remission, even for 
DAS28(CRP) of ≥3.2. Thus, lower disease activity in 
non-responder to infliximab was suitable for application 
of surgery to acquire biologic-free remission. Further-
more, early timing of orthopaedic surgery after toleration 
of infliximab may be important to obtain a high rate of 
remission before increasing DAS28(CRP). The rates of 
remission and biologic-free remission continued at 51.4 
and 77.8 %, respectively, at 104 weeks after orthopaedic 
surgery. Thus, biologic-free remission was stable for a rel-
atively long period in this study. In the ROC analyses, we 
found that DAS28(CRP) below 3.7 showed high potential 
for obtaining biologic-free remission in non-responder 
to infliximab after orthopaedic surgery. This indicated 
that low disease activity may require restoration of joint 
functions by orthopaedic surgery before withdrawing 
biologics.
The limitations of this study are related to its retro-
spective nature, including the small number of patients 
(n = 74) and absence of a non-operative control group for 
comparison with cases of DAS28(CRP) of ≥3.2. Future 
studies should consider the long-term results of biologic-
free remission cases after orthopaedic surgery, and joint 
destruction by X-ray assessment should be evaluated.
Conclusions
Orthopaedic surgery was effective for non-responder to 
infliximab treated cases to obtain remission or biologic-
free remission among RA patients with low disease 
activity.
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